Archives
-
Pazopanib Hydrochloride: Smarter Assay Design
2026-09-22
Pazopanib Hydrochloride research becomes more informative when growth inhibition and cell killing are measured separately. This guide translates the key insight from Schwartz’s dissertation into practical assay design for angiogenesis, renal cell carcinoma, and soft tissue sarcoma studies.
-
Tofacitinib in RA Macrophage Assays
2026-09-21
Tofacitinib, also called CP-690550, supports more than a generic cytokine-inhibition experiment: it can connect STAT5 activity, GM-CSFRα expression, inflammatory macrophage identity, and mitochondrial stress in one workflow. This guide translates recent rheumatoid arthritis macrophage findings into practical dosing, controls, readouts, and troubleshooting decisions.
-
From Stem Cell Hits to Translational Mechanism
2026-09-21
How DiscoveryProbe™ Stem Cell Compound Library Plus can help researchers connect pathway perturbation with interpretable stem cell phenotypes, using high-content screening and the Schistosoma mansoni neoblast model as a translational case study.
-
Carvedilol Phosphate for GPCR and IRI Research
2026-09-20
Carvedilol Phosphate offers a solvent-aware way to perturb beta-adrenergic and alpha-1 signaling in hepatocyte–macrophage ischemia–reperfusion workflows. This guide connects the compound to Arrb2–6-ketoLCA biology while separating reference-study findings from practical assay recommendations.
-
PRMT5, Splicing, and Glutamine Metabolism in Neuroblastoma
2026-09-19
This Cancer Letters study shows that MYCN-amplified neuroblastoma is unusually dependent on PRMT5-regulated RNA splicing, with downstream effects on epitranscriptomic control and glutamine metabolism. Its integrated transcriptomic, metabolic, molecular, and in vivo evidence provides a framework for testing whether GLS1 dependence is a downstream vulnerability rather than a substitute for the upstream PRMT5 mechanism.
-
Liproxstatin-1 (B4987): Reliable Ferroptosis Assays
2026-09-18
This scenario-driven guide explains how Liproxstatin-1 (SKU B4987) can improve mechanistic interpretation of viability, lipid-peroxidation, and ferroptosis assays. It covers assay compatibility, solvent handling, controls, data interpretation, and practical criteria for selecting a dependable ferroptosis inhibitor.
-
SAN-Plexus Assembloids Model Pacemaker Maturation
2026-09-18
This study develops human pluripotent stem cell-derived SAN-plexus assembloids that combine pacemaker organoids, cardiac ganglionated plexus organoids, and atrial-like tissue to model neuro-cardiac control of rhythm. By integrating electrophysiology with human SAN spatial transcriptomics, the authors identify a CGPO-derived prosaposin–GPR37 signaling program associated with pacemaker maturation and conduction function.
-
Berberrubine chloride: Reliable Assay Workflows
2026-09-17
This scenario-driven guide explains how Berberrubine chloride (SKU N2089) can support reproducible cell viability, proliferation, cytotoxicity, and metabolic research workflows. It covers dose selection, DMSO handling, mechanistic interpretation, cross-domain evidence, and practical vendor evaluation.
-
In Vitro Drug Response Evaluation in Cancer
2026-09-17
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent components of an in vitro drug response. This framework supports more precise assay design, time-course interpretation, and translation of pharmacologic findings into cancer research workflows.
-
LNP Lipid Ratios: OFAT Versus DoE
2026-09-16
The reference study shows that conventional lipid molar ratios are robust but not necessarily optimal for mRNA lipid nanoparticles. By comparing one-factor-at-a-time screening with Design of Experiments across manual and automated microfluidic manufacturing, it demonstrates that process conditions, composition, and their interactions shape both physicochemical quality attributes and expression.
-
WP1066: JAK2/STAT3 Inhibitor Workflow
2026-09-16
WP1066 is a cell-permeable pathway probe for linking JAK2/STAT3 activity with cancer-cell survival, proliferation, and apoptosis. This workflow also shows how to use pathway inhibition as a mechanistic control when studying macrophage metabolism and regenerative scaffolds, without confusing pathway blockade with scaffold-driven activation.
-
HyperScript RT SuperMix: Assay Design for PDAC
2026-09-15
HyperScript RT SuperMix for qPCR enables reproducible cDNA synthesis for qPCR in mechanistic pancreatic cancer studies. This article translates the LRRC8A–CAV1 findings into practical RNA-quality, normalization, and assay-design decisions.
-
Tofacitinib Repairs RA Macrophage Dysfunction
2026-09-15
The 2026 reference study identifies a GM-CSF–driven inflammatory and mitochondrial state in rheumatoid arthritis macrophages and shows that Tofacitinib reverses this phenotype more broadly than metabolic inhibitors. Its central contribution is linking GM-CSFRα–STAT5 activity to macrophage inflammatory programming, oxidative stress, and mitochondrial fragmentation across human samples and preclinical models.
-
ATRX-Deficient Glioma and RTK Inhibitor Sensitivity
2026-09-14
Pladevall-Morera and colleagues identified a genotype-linked vulnerability in high-grade glioma: ATRX-deficient cells were more sensitive to several multi-targeted receptor tyrosine kinase and PDGFR inhibitors. The study also found enhanced toxicity when these agents were combined with temozolomide, supporting ATRX status as a useful stratification variable in glioma drug development.
-
Galectin-1, FIP200, and Autophagy in NAFLD
2026-09-14
The reference study identifies a Galectin-1–FIP200 interaction as a previously unrecognized mechanism suppressing hepatic autophagy and promoting steatosis, dyslipidemia, and insulin resistance. Its combination of mouse overexpression, proteomic analysis, structural mapping, and interaction-disrupting mutations provides a useful framework for mechanistic metabolic disorder studies.